Membrane-bound exosomal HSP70 as a biomarker for detection and monitoring of malignant solid tumours: a pilot study.
Fiche publication
Date publication
janvier 2020
Journal
Pilot and feasibility studies
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BERTAUT Aurélie, Dr GARRIDO Carmen, Dr GOBBO Jessica
Tous les auteurs :
Chanteloup G, Cordonnier M, Isambert N, Bertaut A, Marcion G, Garrido C, Gobbo J
Lien Pubmed
Résumé
Cancer is the second leading cause of death globally. Early detection and disease management lead to a better survival rate. Consequently, discovery of novel methods in cancer early diagnosis is a field of active research. Minimally invasive liquid biopsies are generating growing interest. Circulating tumour cells (CTCs) have been identified in patients' blood; nevertheless, these cells are rare and heterogeneous. Exosomes are extracellular nanovesicles released into the extracellular environment via the endosomal vesicle pathway and found in different body fluids. Exosomes deliver bioactive cargo such as proteins, mRNA and miRNA to recipient cells in the tumour environment. We have recently shown that heat shock protein 70 (HSP70) is detected in the membrane of tumour-derived exosomes, in contrast to normal cells. One single cancer cell can release thousands of HSP70-exosomes, facilitating detection. The aim of the pilot study ExoDiag is to determine whether it is possible to detect and quantify HSP70-exosomes in blood in patients with solid cancers.
Mots clés
Cancer diagnosis and monitoring, HSP70-exosomes, Liquid biopsy, Pilot study, Solid tumours
Référence
Pilot Feasibility Stud. 2020 ;6:35